S. Flavell

发表

Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.

D. Flavell, S. Warnes, A. Noss, 1998, Cancer research.

The anti‐CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti‐CD19 immunotoxin directed against human B‐cell lymphoma

G. Packham, D. Flavell, S. Warnes, 2006, British journal of haematology.

Pichia pastoris as a host for secretion of toxic saporin chimeras

R. Ippoliti, M. Fabbrini, M. Colombatti, 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.

B. Morland, D. Flavell, S. Flavell, 1992, British Journal of Cancer.

Opisthorchis viverrini: pathogenesis of infection in immunodeprived hamsters

D. Flavell, S. Flavell, S. Flavell, 1986, Parasite immunology.

Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems

R. Ippoliti, R. Vago, M. Fabbrini, 2015, Microbial Cell Factories.

Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.

D. Flavell, A. Noss, S. Flavell, 1997, British Journal of Cancer.

Therapy of human B‐cell lymphoma bearing scid mice is more effective with anti‐CD19‐and anti‐CD38‐saporin immunotoxins used in combination than with either immunotoxin used alone

D. Flavell, S. Flavell, A. Ramsay, 1995, International journal of cancer.

Therapy of human T‐cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti‐CD7‐saporin immunotoxins containing hindered or non‐hindered disulphide cross‐linkers

D. Flavell, S. Flavell, J. Kohler, 1994, International journal of cancer.

The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells

D. Flavell, S. Flavell, Wendy S Smith, 2021, Biomedicines.

Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents

D. Johnston, D. Flavell, S. Flavell, 2019, Toxins.

Triterpenoid saponin augmention of saporin-based immunotoxin cytotoxicity for human leukaemia and lymphoma cells is partially immunospecific and target molecule dependent

M. Melzig, A. Weng, D. Flavell, 2015, Immunopharmacology and immunotoxicology.

Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.

N. Ling, K. Pulford, D. Flavell, 1997, Cancer research.

Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.

N. Ling, D. Wright, D. Hardie, 1995, British Journal of Cancer.

Localisation of granulocyte macrophage colony-stimulating factor in human long-term bone marrow cultures. Biological and immunocytochemical characterisation.

T. Dexter, T. Allen, D. Flavell, 1993, Journal of cell science.

Membrane cholesterol is essential for triterpenoid saponin augmentation of a saporin-based immunotoxin directed against CD19 on human lymphoma cells.

D. Johnston, D. Flavell, S. Flavell, 2017, Biochimica et biophysica acta. Biomembranes.

Immunotoxin studies in a model of human T-cell acute lymphoblastic leukemia developed in severe combined immune-deficient mice

B. Morland, D. Flavell, S. Flavell, 2007, Cell Biophysics.

Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.

B. Morland, D. Flavell, S. Flavell, 1994, British Journal of Cancer.

The anti‐mitozantrone monoclonal antibody NO‐1, protects acute leukaemia cell lines from the cytotoxic effects of mitozantrone

D. Flavell, S. Flavell, 1991, British journal of haematology.

Anti-CD7 antibody and immunotoxin treatment of human CD7+T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice

D. Flavell, S. Warnes, A. Noss, 2000, British Journal of Cancer.

The TLR3 Agonist Poly Inosinic:Cytidylic Acid Significantly Augments the Therapeutic Activity of an Anti-CD7 Immunotoxin for Human T-Cell Leukaemia

D. Flavell, S. Warnes, S. Flavell, 2019, Biomedicines.

The Role of Cholesterol on Triterpenoid Saponin-Induced Endolysosomal Escape of a Saporin-Based Immunotoxin

D. Johnston, D. Flavell, S. Flavell, 2020, International journal of molecular sciences.

A Flow Cytometric Method to Quantify the Endosomal Escape of a Protein Toxin to the Cytosol of Target Cells

D. Johnston, D. Flavell, S. Flavell, 2019, Pharmaceutical Research.

Opisthorchis viverrini: Partial success in adoptively transferring immunity with spleen cells and serum in the hamster

K. Pattanapanyasat, D. Flavell, S. Flavell, 1980, Journal of Helminthology.

Molecule detected in formalin fixed tissue by antibodies MT1, DF-T1, and L60 (Leu-22) corresponds to CD43 antigen.

R. Warnke, D. Mason, K. Gatter, 1989, Journal of clinical pathology.

High‐dose mitoxantrone and etoposide conditioning in autologous bone marrow transplantation for relapsed Hodgkin's disease

R. Marcus, T. Baglin, D. Flavell, 1992, European journal of haematology.

Development of a sensitive monoclonal antibody-based enzyme-linked immunosorbent assay (ELISA) for mitozantrone.

D. Flavell, S. Flavell, 1988, Journal of immunological methods.

Plant-Derived Type I Ribosome Inactivating Protein-Based Targeted Toxins: A Review of the Clinical Experience

D. Flavell, S. Flavell, 2022, Toxins.

Engineering a switchable toxin: the potential use of PDZ domains in the expression, targeting and activation of modified saporin variants.

S. Gianni, R. Ippoliti, M. Fabbrini, 2010, Protein engineering, design & selection : PEDS.

Optimization of construct design and fermentation strategy for the production of bioactive ATF-SAP, a saporin based anti-tumoral uPAR-targeted chimera

F. Angelucci, R. Ippoliti, D. Porro, 2016, Microbial Cell Factories.

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin

D. Flavell, S. Warnes, A. Noss, 2001, British Journal of Cancer.

Comparison of immunotoxins bearing a single saporin molecule with multiple toxin conjugates.

D. Flavell, S. Flavell, 2001, Methods in molecular biology.

Dissecting the Entry Route of Saporin-based a-CD7 Immunotoxins in Human T-Cell Acute Lymphoblastic Leukaemia Cells

R. Ippoliti, R. Vago, M. Fabbrini, 2013 .

Opisthorchis viverrini: the relationship between egg production, worm size and intensity of infection in the hamster.

D. Flavell, S. Flavell, G. Field, 1983, Transactions of the Royal Society of Tropical Medicine and Hygiene.

Characteristics and performance of a bispecific F (ab'gamma)2 antibody for delivering saporin to a CD7+ human acute T-cell leukaemia cell line.

B. Morland, D. Flavell, S. Flavell, 1991, British Journal of Cancer.

Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cells

R. Ippoliti, R. Vago, M. Fabbrini, 2005, The FEBS journal.

Comparison of the performance of anti‐CD7 and anti‐CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T‐cell acute lymphoblastic leukemia cell line

D. Flavell, S. Flavell, L. Emery, 1995, Hematological oncology.

European Clinical Trials Directive: responses made to MHRA consultation letter MLX 287

R. Sullivan, D. Flavell, S. Flavell, 2003, The Lancet.